New and evolving immunotherapy in inflammatory bowel disease

dc.contributor.authorRaad, Mohamad A.
dc.contributor.authorChams, Nour H.
dc.contributor.authorSharara, Ala I.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Gastroenterology and Hepatology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:48:40Z
dc.date.available2025-01-24T11:48:40Z
dc.date.issued2016
dc.description.abstractBackground: Crohn's disease and ulcerative colitis are chronic inflammatory disorders associated with a dysregulated adaptive and innate immune response to gut commensals in genetically susceptible individuals. The pathogenesis of inflammatory bowel disease is complex, and the disease is characterized by significant phenotypic and genotypic heterogeneity. Summary: The introduction of anti-TNF biologics has resulted in improved clinical outcomes in patients with severe and moderately severe disease, but the current treatment paradigm continues to depend on systemic immunosuppression (steroids and immunomodulators) and surgical intervention in a significant number of patients, underscoring a significant unmet need. More recently, a number of genetic and immunologic abnormalities have been unraveled including aberrant intestinal mucosal defense function, abnormal intestinal permeability, dysregulated bacterial antigen processing by macrophages and presentation to T cells, cellular immune regulation and signaling, cytokine production, and leukocyte trafficking. Key Messages: Understanding these molecular mechanisms and effector pathways presents an opportunity for the development of new and improved targeted therapies. © 2016 S. Karger AG, Basel.
dc.identifier.doihttps://doi.org/10.1159/000445986
dc.identifier.eid2-s2.0-85054399467
dc.identifier.urihttp://hdl.handle.net/10938/30833
dc.language.isoen
dc.publisherS. Karger AG
dc.relation.ispartofInflammatory Intestinal Diseases
dc.sourceScopus
dc.subjectBiologics
dc.subjectCrohn's disease
dc.subjectInflammatory bowel disease
dc.subjectTreatment
dc.subjectUlcerative colitis
dc.subjectAnrukinzumab
dc.subjectEtrolizumab
dc.subjectInterleukin 12
dc.subjectInterleukin 13
dc.subjectInterleukin 23
dc.subjectJanus kinase
dc.subjectNatalizumab
dc.subjectSmad7 protein
dc.subjectSphingosine kinase 1
dc.subjectStat protein
dc.subjectTofacitinib
dc.subjectUstekinumab
dc.subjectVedolizumab
dc.subjectCell adhesion
dc.subjectCrohn disease
dc.subjectDrug indication
dc.subjectDrug response
dc.subjectHuman
dc.subjectImmunotherapy
dc.subjectLeukocyte
dc.subjectMulticenter study (topic)
dc.subjectNonhuman
dc.subjectPhase 1 clinical trial (topic)
dc.subjectPhase 2 clinical trial (topic)
dc.subjectPhase 3 clinical trial (topic)
dc.subjectPriority journal
dc.subjectRandomized controlled trial (topic)
dc.subjectReview
dc.subjectSignal transduction
dc.titleNew and evolving immunotherapy in inflammatory bowel disease
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2016-9426.pdf
Size:
1.33 MB
Format:
Adobe Portable Document Format